SlideShare a Scribd company logo
1 of 16
Download to read offline
1
MR Contrast Agents for
Vulnerable Plaque Imaging
Philip Graham, PhD
EPIX Medical, Inc.
Cambridge, MA 02142
2
MS-325: Vascular Contrast
Agent
• Albumin binding
•Extends plasma
t1/2
•4-10X increase
in signal
•Slows ECS
uptake
• Phase III
angiography trials
ongoing
• Hypothesis: MS-
325, an albumin-
targeted Gd
contrast agent,
highlights inflamed
vessel wall and
facilitates plaque Equilibrium Phase MS-325Arterial Phase
3
Vessel Wall Enhancement with
MS-325
Courtesy of: T. Grist (University of Wisconsin, Madison, WI)
4
Jeffrey H. Maki1,2
, Gregory J. Wilson1
,
Randall B. Lauffer3
, Robert M. Weisskoff3
,
Chun Yuan2
1 - Puget Sound VAHCS, Seattle, WA
2 - University of Washington, Seattle, WA
3 - EPIX Medical, Cambridge, MA
Vessel Wall Enhancement with MS-325
MRI Facilitates Plaque Detection and
Characterization
5
Vessel Wall Enhancement
with MS-325
• Atherosclerosis = inflammation
• Leaky capillaries supplying vessel
wall
– Increased albumin conc. in wall
• Consistent enhancement of wall in
patients with MS-325
• Implications for stenosis
identification and quantitation (and
plaque burden)
• Enhancement may correlate with
risk of rupture
Aorta
Right Iliac
Artery
Vessel
Wall
Vessel
Wall
Courtesy of: Dr. J Maki (UW/Puget S VA)
6
Arterial Phase Equilibrium Phase MS-325
Source Images - Left External Iliac Artery
Artery
Vein
7
0
0.5
1
1.5
2
2.5
3
Adj to Plaque No Plaque
Wall Thickness (mm) Related to Plaque
Results
Adj to Plaque No Plaque
P < 0.01
8
Results
• Strong wall enhancement with MS-325 because of
increased capillary volume and binding to
extravasated albumin
• Low signal between wall and lumen represents
atherosclerotic plaque.
• Prolonged enhancement of wall and lumen allows
high resolution detection of plaque burden
• Potentially straightforward method of plaque
visualization and quantification
• ? Follow statin therapy
9
Pharmacological trigger
histamine = vasoconstrictor -> increases mechanical force on fibrous cap -> plaque
disruption
Russells viper venom -> triggers blood clotting cascade
fresh thrombus
lipid core?
thin fibrous cap?
fresh thrombus
vasoconstriction
pre-trigger
post-trigger disrupted plaque
T2w
Visualization of Plaque Rupture in Rabbit Model
Johnstone MT, Botnar RM, Perez AS, Stewart R, Quist W, Hamilton J, Manning
WJ. In Vivo Magnetic Resonance Imaging of Experimental Thrombosis in a
Rabbit Model. Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1556-60.
Courtesy: Johnstone, Botnar, Manning: BIDMC
10
baseline
MS-325
MS-325 improves Plaque Visualization
plaque
contrast uptake no uptake
wall
plaque
thrombus
MS-325
Post-trigger
Courtesy: Johnstone, Botnar, Manning: BIDMC
11
Direct Clot Detection with Fibrin-
Targeted Contrast Agent
• Fibrin targeting lead discovered in a collaboration with
Dyax
• MR contrast agents EP-1242 and EP-1873 resulted from
extensive modifications by EPIX of the original leads
• Elimination profile similar to Magnevist®
EP-1242 Enhanced Carotid Clot in Guinea Pig
In collaboration with Z. Fayad, Ph.D., Mt. Sinai, New York
12
To be annotated, final copy will be printed high definition
Post Gd-BSA (angiography)
Pre contrast
1 minute post EP-1873
36 minute post EP-1873
Jugular
thrombus
Rabbit Carotid
thrombus
Jugular
thrombus
Carotid
thrombus
In collaboration with E. Kent Yucel, Lee Zhou (?) Brigham & Women’s, Boston
13
Pre contrast
10min
1.5h
1h
Post EP-1873 (fibrin agent)
aorta
thrombus
thrombus
thrombus
Botnar RM, Perez AP, Johnstone MT, Manning WJ
14
Pre contrast
10min
1.5h
1h
Post EP-1873 (fibrin agent)
Botnar RM, Perez AP, Manning WJ, Johnstone MT
15
Pre contrast 10min 1.5h
Post EP-1873 (fibrin agent)
aorta
thrombus thrombus
Botnar RM, Perez AP, Manning WJ, Johnstone MT
16
Summary
• Prototype clot-enhancing agents for MRI
– High binding affinity and selectivity to human fibrin
– Rapid Enhancement of arterial and venous clots
– Good in vivo clot uptake and enhancement
– No effects on clotting cascade
• Thrombotic consequences of plaque rupture
directly visible on standard MR scans
– Potential for assessing thromboembolic risk in a
variety of vascular beds
– Follow clot resolution after treatment
administration?

More Related Content

What's hot

expression of eukariotic gene in bacteria
expression of eukariotic gene in bacteriaexpression of eukariotic gene in bacteria
expression of eukariotic gene in bacteriahimanikulshrestha2
 
Bacterial gene transfer
Bacterial gene transferBacterial gene transfer
Bacterial gene transferAthiraOk1
 
Dr. ladli kishore (microbial genetics and variation) (1)
Dr. ladli kishore (microbial genetics and variation) (1)Dr. ladli kishore (microbial genetics and variation) (1)
Dr. ladli kishore (microbial genetics and variation) (1)Drladlikishore2015
 
Park et al Immunity 1996 (dragged)
Park et al Immunity 1996 (dragged)Park et al Immunity 1996 (dragged)
Park et al Immunity 1996 (dragged)Hyunsun Park
 
Genetic technology
Genetic technologyGenetic technology
Genetic technologymiller4075
 
Genetic engineering, issues and concern
Genetic engineering, issues and concernGenetic engineering, issues and concern
Genetic engineering, issues and concerncbsua
 
Gene therapy for monogenic diseases
Gene therapy for monogenic diseasesGene therapy for monogenic diseases
Gene therapy for monogenic diseasesSaira Fatima
 
Abstract: CHARACTERIZATION OF MITOCHONDRIAL MUTATION m.8993T>C INHERITANCE OF...
Abstract: CHARACTERIZATION OF MITOCHONDRIAL MUTATION m.8993T>C INHERITANCE OF...Abstract: CHARACTERIZATION OF MITOCHONDRIAL MUTATION m.8993T>C INHERITANCE OF...
Abstract: CHARACTERIZATION OF MITOCHONDRIAL MUTATION m.8993T>C INHERITANCE OF...Weerasinghe AL Chamara
 
64 andrew fire - 6506559 - genetic inhibition by double-stranded rna
64   andrew fire - 6506559 - genetic inhibition by double-stranded rna64   andrew fire - 6506559 - genetic inhibition by double-stranded rna
64 andrew fire - 6506559 - genetic inhibition by double-stranded rnaMello_Patent_Registry
 
Introduction to recombination DNA technology
Introduction to recombination DNA technologyIntroduction to recombination DNA technology
Introduction to recombination DNA technologyIndrajaDoradla
 

What's hot (15)

Taruna Ikrar
Taruna IkrarTaruna Ikrar
Taruna Ikrar
 
SFN-2013
SFN-2013SFN-2013
SFN-2013
 
expression of eukariotic gene in bacteria
expression of eukariotic gene in bacteriaexpression of eukariotic gene in bacteria
expression of eukariotic gene in bacteria
 
Bacterial gene transfer
Bacterial gene transferBacterial gene transfer
Bacterial gene transfer
 
CMA school topic 2
CMA school topic 2CMA school topic 2
CMA school topic 2
 
Dr. ladli kishore (microbial genetics and variation) (1)
Dr. ladli kishore (microbial genetics and variation) (1)Dr. ladli kishore (microbial genetics and variation) (1)
Dr. ladli kishore (microbial genetics and variation) (1)
 
Park et al Immunity 1996 (dragged)
Park et al Immunity 1996 (dragged)Park et al Immunity 1996 (dragged)
Park et al Immunity 1996 (dragged)
 
Genetic technology
Genetic technologyGenetic technology
Genetic technology
 
Genetic engineering, issues and concern
Genetic engineering, issues and concernGenetic engineering, issues and concern
Genetic engineering, issues and concern
 
Gene therapy for monogenic diseases
Gene therapy for monogenic diseasesGene therapy for monogenic diseases
Gene therapy for monogenic diseases
 
Abstract: CHARACTERIZATION OF MITOCHONDRIAL MUTATION m.8993T>C INHERITANCE OF...
Abstract: CHARACTERIZATION OF MITOCHONDRIAL MUTATION m.8993T>C INHERITANCE OF...Abstract: CHARACTERIZATION OF MITOCHONDRIAL MUTATION m.8993T>C INHERITANCE OF...
Abstract: CHARACTERIZATION OF MITOCHONDRIAL MUTATION m.8993T>C INHERITANCE OF...
 
64 andrew fire - 6506559 - genetic inhibition by double-stranded rna
64   andrew fire - 6506559 - genetic inhibition by double-stranded rna64   andrew fire - 6506559 - genetic inhibition by double-stranded rna
64 andrew fire - 6506559 - genetic inhibition by double-stranded rna
 
Gene technology
Gene technologyGene technology
Gene technology
 
Introduction to recombination DNA technology
Introduction to recombination DNA technologyIntroduction to recombination DNA technology
Introduction to recombination DNA technology
 
severe combined immunodeficiency
severe combined immunodeficiencysevere combined immunodeficiency
severe combined immunodeficiency
 

Viewers also liked

225 animal models of heart attack part 2
225 animal models of heart attack part 2225 animal models of heart attack part 2
225 animal models of heart attack part 2SHAPE Society
 
131 the evolution of coronary atherosclerosis
131 the evolution of coronary atherosclerosis131 the evolution of coronary atherosclerosis
131 the evolution of coronary atherosclerosisSHAPE Society
 
039 mr contrast agents for vulnerable plaque imaging
039 mr contrast agents for vulnerable plaque imaging039 mr contrast agents for vulnerable plaque imaging
039 mr contrast agents for vulnerable plaque imagingSHAPE Society
 
070 visualization of atherosclerotic vulnerable plaque
070 visualization of atherosclerotic vulnerable plaque070 visualization of atherosclerotic vulnerable plaque
070 visualization of atherosclerotic vulnerable plaqueSHAPE Society
 
3rd vp symposium jang
3rd vp symposium jang3rd vp symposium jang
3rd vp symposium jangSHAPE Society
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for printSHAPE Society
 
195 hepatic synthesis and secretion of vldl
195 hepatic synthesis and secretion of vldl195 hepatic synthesis and secretion of vldl
195 hepatic synthesis and secretion of vldlSHAPE Society
 
209 trans blood vision™
209 trans blood vision™209 trans blood vision™
209 trans blood vision™SHAPE Society
 
168 catheter based detection of vulnerable plaque
168 catheter based detection of vulnerable plaque168 catheter based detection of vulnerable plaque
168 catheter based detection of vulnerable plaqueSHAPE Society
 
159 spio uptake by macrophages
159 spio uptake by macrophages159 spio uptake by macrophages
159 spio uptake by macrophagesSHAPE Society
 
190 virus infected monocyes
190 virus infected monocyes190 virus infected monocyes
190 virus infected monocyesSHAPE Society
 
185 towards the future cath lab
185 towards the future cath lab185 towards the future cath lab
185 towards the future cath labSHAPE Society
 
160 5th vulnerable plaque symposium
160 5th vulnerable plaque symposium160 5th vulnerable plaque symposium
160 5th vulnerable plaque symposiumSHAPE Society
 
098 red wine and heart disease
098 red wine and heart disease098 red wine and heart disease
098 red wine and heart diseaseSHAPE Society
 
3rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 13rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 1SHAPE Society
 
120 mr imaging for the evaluation of carotid atherosclerosis
120 mr imaging for the evaluation of carotid atherosclerosis120 mr imaging for the evaluation of carotid atherosclerosis
120 mr imaging for the evaluation of carotid atherosclerosisSHAPE Society
 

Viewers also liked (20)

225 animal models of heart attack part 2
225 animal models of heart attack part 2225 animal models of heart attack part 2
225 animal models of heart attack part 2
 
Acc 2005-1, v pl-vp
Acc 2005-1, v pl-vpAcc 2005-1, v pl-vp
Acc 2005-1, v pl-vp
 
131 the evolution of coronary atherosclerosis
131 the evolution of coronary atherosclerosis131 the evolution of coronary atherosclerosis
131 the evolution of coronary atherosclerosis
 
039 mr contrast agents for vulnerable plaque imaging
039 mr contrast agents for vulnerable plaque imaging039 mr contrast agents for vulnerable plaque imaging
039 mr contrast agents for vulnerable plaque imaging
 
070 visualization of atherosclerotic vulnerable plaque
070 visualization of atherosclerotic vulnerable plaque070 visualization of atherosclerotic vulnerable plaque
070 visualization of atherosclerotic vulnerable plaque
 
3rd vp symposium jang
3rd vp symposium jang3rd vp symposium jang
3rd vp symposium jang
 
Acc 2002 microarray mehran for print
Acc 2002 microarray mehran for printAcc 2002 microarray mehran for print
Acc 2002 microarray mehran for print
 
031
031031
031
 
195 hepatic synthesis and secretion of vldl
195 hepatic synthesis and secretion of vldl195 hepatic synthesis and secretion of vldl
195 hepatic synthesis and secretion of vldl
 
209 trans blood vision™
209 trans blood vision™209 trans blood vision™
209 trans blood vision™
 
168 catheter based detection of vulnerable plaque
168 catheter based detection of vulnerable plaque168 catheter based detection of vulnerable plaque
168 catheter based detection of vulnerable plaque
 
243 b cell
243 b cell243 b cell
243 b cell
 
159 spio uptake by macrophages
159 spio uptake by macrophages159 spio uptake by macrophages
159 spio uptake by macrophages
 
190 virus infected monocyes
190 virus infected monocyes190 virus infected monocyes
190 virus infected monocyes
 
165 pressure wire
165 pressure wire165 pressure wire
165 pressure wire
 
185 towards the future cath lab
185 towards the future cath lab185 towards the future cath lab
185 towards the future cath lab
 
160 5th vulnerable plaque symposium
160 5th vulnerable plaque symposium160 5th vulnerable plaque symposium
160 5th vulnerable plaque symposium
 
098 red wine and heart disease
098 red wine and heart disease098 red wine and heart disease
098 red wine and heart disease
 
3rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 13rd vulnerable plaque rumberger 3 16-02 1
3rd vulnerable plaque rumberger 3 16-02 1
 
120 mr imaging for the evaluation of carotid atherosclerosis
120 mr imaging for the evaluation of carotid atherosclerosis120 mr imaging for the evaluation of carotid atherosclerosis
120 mr imaging for the evaluation of carotid atherosclerosis
 

Similar to 134 mr contrast agents for vulnerable plaque imaging

135 contrast enhanced mri of vulnerable plaque
135 contrast enhanced mri of vulnerable plaque135 contrast enhanced mri of vulnerable plaque
135 contrast enhanced mri of vulnerable plaqueSHAPE Society
 
099 inhibitory effect on arterial injury
099 inhibitory effect on arterial injury099 inhibitory effect on arterial injury
099 inhibitory effect on arterial injurySHAPE Society
 
Role of contrast enhanced ultrasonography in characterization of hepatobiliar...
Role of contrast enhanced ultrasonography in characterization of hepatobiliar...Role of contrast enhanced ultrasonography in characterization of hepatobiliar...
Role of contrast enhanced ultrasonography in characterization of hepatobiliar...Dr. Muhammad Bin Zulfiqar
 
The role of inflammatory reaction in chronic venous disease of the lower limb
The role of inflammatory reaction in chronic venous disease of the lower limbThe role of inflammatory reaction in chronic venous disease of the lower limb
The role of inflammatory reaction in chronic venous disease of the lower limbKETAN VAGHOLKAR
 
140 mr imaging of fibrin
140 mr imaging of fibrin140 mr imaging of fibrin
140 mr imaging of fibrinSHAPE Society
 
Newer trends in interventional cardiology
Newer trends in interventional cardiologyNewer trends in interventional cardiology
Newer trends in interventional cardiologySuraj Bhorkar
 
Dr Dake presentation ICCCV nov 2011
Dr Dake presentation ICCCV nov 2011Dr Dake presentation ICCCV nov 2011
Dr Dake presentation ICCCV nov 2011Sylvie Tuslanes
 

Similar to 134 mr contrast agents for vulnerable plaque imaging (19)

Mr contrast agents for vp imaging philip graham
Mr contrast agents for vp imaging  philip grahamMr contrast agents for vp imaging  philip graham
Mr contrast agents for vp imaging philip graham
 
Phil graham new
Phil graham newPhil graham new
Phil graham new
 
Vp
VpVp
Vp
 
Contrast enhanced mri of the vp black or white
Contrast enhanced mri of the vp   black or whiteContrast enhanced mri of the vp   black or white
Contrast enhanced mri of the vp black or white
 
Noninvasive mr imaging of plaque inflammation
Noninvasive mr imaging of plaque inflammationNoninvasive mr imaging of plaque inflammation
Noninvasive mr imaging of plaque inflammation
 
135 contrast enhanced mri of vulnerable plaque
135 contrast enhanced mri of vulnerable plaque135 contrast enhanced mri of vulnerable plaque
135 contrast enhanced mri of vulnerable plaque
 
Contrast enhanced mri of vulnerable plaque black or white
Contrast enhanced mri of vulnerable plaque black or whiteContrast enhanced mri of vulnerable plaque black or white
Contrast enhanced mri of vulnerable plaque black or white
 
Maziar2
Maziar2Maziar2
Maziar2
 
135 contrast enhanced mri of vulnerable plaque
135 contrast enhanced mri of vulnerable plaque135 contrast enhanced mri of vulnerable plaque
135 contrast enhanced mri of vulnerable plaque
 
099 inhibitory effect on arterial injury
099 inhibitory effect on arterial injury099 inhibitory effect on arterial injury
099 inhibitory effect on arterial injury
 
Role of contrast enhanced ultrasonography in characterization of hepatobiliar...
Role of contrast enhanced ultrasonography in characterization of hepatobiliar...Role of contrast enhanced ultrasonography in characterization of hepatobiliar...
Role of contrast enhanced ultrasonography in characterization of hepatobiliar...
 
Esv2n32
Esv2n32Esv2n32
Esv2n32
 
The role of inflammatory reaction in chronic venous disease of the lower limb
The role of inflammatory reaction in chronic venous disease of the lower limbThe role of inflammatory reaction in chronic venous disease of the lower limb
The role of inflammatory reaction in chronic venous disease of the lower limb
 
Editorialslides v2n9
Editorialslides v2n9Editorialslides v2n9
Editorialslides v2n9
 
Positive remodeling for ralph
Positive remodeling for ralphPositive remodeling for ralph
Positive remodeling for ralph
 
140 mr imaging of fibrin
140 mr imaging of fibrin140 mr imaging of fibrin
140 mr imaging of fibrin
 
140 mr imaging of fibrin
140 mr imaging of fibrin140 mr imaging of fibrin
140 mr imaging of fibrin
 
Newer trends in interventional cardiology
Newer trends in interventional cardiologyNewer trends in interventional cardiology
Newer trends in interventional cardiology
 
Dr Dake presentation ICCCV nov 2011
Dr Dake presentation ICCCV nov 2011Dr Dake presentation ICCCV nov 2011
Dr Dake presentation ICCCV nov 2011
 

More from SHAPE Society

Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stoneSHAPE Society
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 fSHAPE Society
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)SHAPE Society
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)SHAPE Society
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)SHAPE Society
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for printSHAPE Society
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermographySHAPE Society
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st centurySHAPE Society
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosisSHAPE Society
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factorSHAPE Society
 
511 first steps towards understanding
511 first steps towards understanding511 first steps towards understanding
511 first steps towards understandingSHAPE Society
 

More from SHAPE Society (20)

Barth imt
Barth imtBarth imt
Barth imt
 
Braunwald
BraunwaldBraunwald
Braunwald
 
Acc vp-org 3-02 stone
Acc vp-org 3-02 stoneAcc vp-org 3-02 stone
Acc vp-org 3-02 stone
 
101205 shape aha 2005 f
101205 shape aha 2005 f101205 shape aha 2005 f
101205 shape aha 2005 f
 
Acc v porg becker
Acc v porg beckerAcc v porg becker
Acc v porg becker
 
Acc presentation macrophage (1)
Acc presentation macrophage (1)Acc presentation macrophage (1)
Acc presentation macrophage (1)
 
Acc v porg
Acc v porgAcc v porg
Acc v porg
 
Acc presentation (1)
Acc presentation (1)Acc presentation (1)
Acc presentation (1)
 
Ac cculprit
Ac cculpritAc cculprit
Ac cculprit
 
Acc presentation lipid coated(2)
Acc presentation lipid coated(2)Acc presentation lipid coated(2)
Acc presentation lipid coated(2)
 
Acc booth inventory
Acc booth inventoryAcc booth inventory
Acc booth inventory
 
Acc 04 vuln pt
Acc 04 vuln ptAcc 04 vuln pt
Acc 04 vuln pt
 
Acc 2002 mehran for print
Acc 2002  mehran for printAcc 2002  mehran for print
Acc 2002 mehran for print
 
Acc2002 thermography
Acc2002 thermographyAcc2002 thermography
Acc2002 thermography
 
A20 gene
A20 geneA20 gene
A20 gene
 
#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century#1 killer of human beings in the 21st century
#1 killer of human beings in the 21st century
 
A20 is an atherosclerosis
A20 is an atherosclerosisA20 is an atherosclerosis
A20 is an atherosclerosis
 
103100
103100103100
103100
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
 
511 first steps towards understanding
511 first steps towards understanding511 first steps towards understanding
511 first steps towards understanding
 

Recently uploaded

Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)1922Jaygohel
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
AI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsAI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsEmily Kunka, MS, CCRP
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essAbhishekKumar524514
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Employability skills, work experience presentation
Employability skills, work experience presentationEmployability skills, work experience presentation
Employability skills, work experience presentationmarwaahmad357
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 

Recently uploaded (20)

American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)A presentation on Thermal gravimetry analysis (TGA)
A presentation on Thermal gravimetry analysis (TGA)
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
AI in Action: Elevating Patient Insights
AI in Action: Elevating Patient InsightsAI in Action: Elevating Patient Insights
AI in Action: Elevating Patient Insights
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Understanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well essUnderstanding AIDS:a roadmap to well ess
Understanding AIDS:a roadmap to well ess
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Employability skills, work experience presentation
Employability skills, work experience presentationEmployability skills, work experience presentation
Employability skills, work experience presentation
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 

134 mr contrast agents for vulnerable plaque imaging

  • 1. 1 MR Contrast Agents for Vulnerable Plaque Imaging Philip Graham, PhD EPIX Medical, Inc. Cambridge, MA 02142
  • 2. 2 MS-325: Vascular Contrast Agent • Albumin binding •Extends plasma t1/2 •4-10X increase in signal •Slows ECS uptake • Phase III angiography trials ongoing • Hypothesis: MS- 325, an albumin- targeted Gd contrast agent, highlights inflamed vessel wall and facilitates plaque Equilibrium Phase MS-325Arterial Phase
  • 3. 3 Vessel Wall Enhancement with MS-325 Courtesy of: T. Grist (University of Wisconsin, Madison, WI)
  • 4. 4 Jeffrey H. Maki1,2 , Gregory J. Wilson1 , Randall B. Lauffer3 , Robert M. Weisskoff3 , Chun Yuan2 1 - Puget Sound VAHCS, Seattle, WA 2 - University of Washington, Seattle, WA 3 - EPIX Medical, Cambridge, MA Vessel Wall Enhancement with MS-325 MRI Facilitates Plaque Detection and Characterization
  • 5. 5 Vessel Wall Enhancement with MS-325 • Atherosclerosis = inflammation • Leaky capillaries supplying vessel wall – Increased albumin conc. in wall • Consistent enhancement of wall in patients with MS-325 • Implications for stenosis identification and quantitation (and plaque burden) • Enhancement may correlate with risk of rupture Aorta Right Iliac Artery Vessel Wall Vessel Wall Courtesy of: Dr. J Maki (UW/Puget S VA)
  • 6. 6 Arterial Phase Equilibrium Phase MS-325 Source Images - Left External Iliac Artery Artery Vein
  • 7. 7 0 0.5 1 1.5 2 2.5 3 Adj to Plaque No Plaque Wall Thickness (mm) Related to Plaque Results Adj to Plaque No Plaque P < 0.01
  • 8. 8 Results • Strong wall enhancement with MS-325 because of increased capillary volume and binding to extravasated albumin • Low signal between wall and lumen represents atherosclerotic plaque. • Prolonged enhancement of wall and lumen allows high resolution detection of plaque burden • Potentially straightforward method of plaque visualization and quantification • ? Follow statin therapy
  • 9. 9 Pharmacological trigger histamine = vasoconstrictor -> increases mechanical force on fibrous cap -> plaque disruption Russells viper venom -> triggers blood clotting cascade fresh thrombus lipid core? thin fibrous cap? fresh thrombus vasoconstriction pre-trigger post-trigger disrupted plaque T2w Visualization of Plaque Rupture in Rabbit Model Johnstone MT, Botnar RM, Perez AS, Stewart R, Quist W, Hamilton J, Manning WJ. In Vivo Magnetic Resonance Imaging of Experimental Thrombosis in a Rabbit Model. Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1556-60. Courtesy: Johnstone, Botnar, Manning: BIDMC
  • 10. 10 baseline MS-325 MS-325 improves Plaque Visualization plaque contrast uptake no uptake wall plaque thrombus MS-325 Post-trigger Courtesy: Johnstone, Botnar, Manning: BIDMC
  • 11. 11 Direct Clot Detection with Fibrin- Targeted Contrast Agent • Fibrin targeting lead discovered in a collaboration with Dyax • MR contrast agents EP-1242 and EP-1873 resulted from extensive modifications by EPIX of the original leads • Elimination profile similar to Magnevist® EP-1242 Enhanced Carotid Clot in Guinea Pig In collaboration with Z. Fayad, Ph.D., Mt. Sinai, New York
  • 12. 12 To be annotated, final copy will be printed high definition Post Gd-BSA (angiography) Pre contrast 1 minute post EP-1873 36 minute post EP-1873 Jugular thrombus Rabbit Carotid thrombus Jugular thrombus Carotid thrombus In collaboration with E. Kent Yucel, Lee Zhou (?) Brigham & Women’s, Boston
  • 13. 13 Pre contrast 10min 1.5h 1h Post EP-1873 (fibrin agent) aorta thrombus thrombus thrombus Botnar RM, Perez AP, Johnstone MT, Manning WJ
  • 14. 14 Pre contrast 10min 1.5h 1h Post EP-1873 (fibrin agent) Botnar RM, Perez AP, Manning WJ, Johnstone MT
  • 15. 15 Pre contrast 10min 1.5h Post EP-1873 (fibrin agent) aorta thrombus thrombus Botnar RM, Perez AP, Manning WJ, Johnstone MT
  • 16. 16 Summary • Prototype clot-enhancing agents for MRI – High binding affinity and selectivity to human fibrin – Rapid Enhancement of arterial and venous clots – Good in vivo clot uptake and enhancement – No effects on clotting cascade • Thrombotic consequences of plaque rupture directly visible on standard MR scans – Potential for assessing thromboembolic risk in a variety of vascular beds – Follow clot resolution after treatment administration?

Editor's Notes

  1. &amp;lt;number&amp;gt;
  2. &amp;lt;number&amp;gt;
  3. Long segments of wall enhancement seen, even in relatively normal vessels per angiography Wall thickness greatest in areas of greatest atherosclerosis burden
  4. &amp;lt;number&amp;gt;